P/E ratio for Alnylam Pharmaceuticals (ALNY)

P/E ratio history for Alnylam Pharmaceuticals from 2004 to 2026

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Novartis NVS	21.3	-72.45%	🇨🇭 Switzerland
Sanofi SNY	16.7	-78.38%	🇫🇷 France
Regeneron Pharmaceuticals REGN	16.8	-78.35%	🇺🇸 USA
Sarepta Therapeutics SRPT	-2.25	-102.90%	🇺🇸 USA
Regulus Therapeutics RGLS	-11.2	-114.44%	🇺🇸 USA
OPKO Health OPK	-4.58	-105.92%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	25.8	-66.71%	🇮🇱 Israel
Arrowhead Pharmaceuticals ARWR	228	194.06%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.